SLC5A2 and Hyperglycemia: The first disorder is a likely common manifestation of a newly emerging class of targeted cancer therapy (ie, hyperglycemia associated with PI3K inhibitors), while the second disorder is an uncommon manifestation of a frequently used oral hypoglycemic medication (ie, euglycemic ketoacidosis with SGLT2 inhibition).